Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00752427 | 24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia | PHASE3 | COMPLETED | 86 | — | — | Jun 1, 2004 | Nov 1, 2005 | Jun 8, 2011 | - | — |
| NCT00210769 | A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia | PHASE3 | COMPLETED | 203 | — | — | Jan 1, 2004 | Dec 1, 2005 | May 18, 2011 | - | — |
| NCT00758030 | Study Evaluating and Comparing Single Dose and Multiple Dose Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Adults. | PHASE1 | COMPLETED | 60 | — | — | Mar 1, 2004 | Jul 1, 2004 | Jun 8, 2011 | - | — |
| Name | Type | Description |
|---|---|---|
| Paliperidone ER OROS® | DRUG | - |
| paliperidone ER Oros | DRUG | - |
Inclusion Criteria: * Subjects who had completed the double-blind phase or discontinued due to lack of efficacy after at least 21 days of treatment, who signed the informed consent for the open-label phase, and who the investigator agreed that open-label treatment was in the best interest of the su...